Abstract:The Cystine-xCT transporter-Glutathione (GSH)-GPX4 axis is the canonical pathway to protect against ferroptosis. While not required for ferroptosis-inducing compounds (FINs) targeting GPX4, FINs targeting the xCT transporter require mitochondria and its lipid peroxidation to trigger ferroptosis. However, the mechanism underlying the difference between these FINs is still unknown. Given that cysteine is also required for coenzyme A (CoA) biosynthesis, here we show that CoA supplementation specifically prevents ferroptosis induced by xCT inhibitors but not GPX4 inhibitors. We find that, auranofin, a thioredoxin reductase inhibitor, abolishes the protective effect of CoA. We also find that CoA availability determines the enzymatic activity of thioredoxin reductase, but not thioredoxin. Importantly, the mitochondrial thioredoxin system, but not the cytosolic thioredoxin system, determines CoA-mediated ferroptosis inhibition. Our data show that the CoA regulates the in vitro enzymatic activity of mitochondrial thioredoxin reductase (TXNRD2) by covalently modifying the thiol group of cysteine (CoAlation) on Cys-483. Replacing Cys-483 with alanine on TXNRD2 abolishes its in vitro enzymatic activity and ability to protect cells from ferroptosis. Targeting xCT to limit cysteine import and, therefore, CoA biosynthesis reduced CoAlation on TXNRD2, an effect that was rescued by CoA supplementation. Furthermore, the fibroblasts from patients with disrupted CoA metabolism demonstrate increased mitochondrial lipid peroxidation. In organotypic brain slice cultures, inhibition of CoA biosynthesis leads to an oxidized thioredoxin system, mitochondrial lipid peroxidation, and loss in cell viability, which were all rescued by ferrostatin-1. These findings identify CoA-mediated post-translation modification to regulate the thioredoxin system as an alternative ferroptosis protection pathway with potential clinical relevance for patients with disrupted CoA metabolism.

Cysteine and homocysteine can be exploited by GPX4 in ferroptosis inhibition independent of GSH synthesis

A Class of Disulfide Compounds Suppresses Ferroptosis by Stabilizing GPX4

Post-Translational Modification of GPX4 is a Promising Target for Treating Ferroptosis-Related Diseases

Targeting GPX4 in ferroptosis and cancer: chemical strategies and challenges

GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment

GPX4, ferroptosis, and diseases

Directly Targeting Glutathione Peroxidase 4 May Be More Effective Than Disrupting Glutathione on Ferroptosis-Based Cancer Therapy

Coenzyme A protects against ferroptosis via CoAlation of thioredoxin reductase 2

System Xc−/GSH/GPX4 axis: An important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy

mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation

Peroxisome proliferator-activated receptor δ rescues xCT-deficient cells from ferroptosis by targeting peroxisomes

GPX4 and vitamin E cooperatively protect hematopoietic stem and progenitor cells from lipid peroxidation and ferroptosis

A potent GPX4 degrader to induce ferroptosis in HT1080 cells

The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1

Discovery of a Potent Glutathione Peroxidase 4 Inhibitor As a Selective Ferroptosis Inducer.

Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis

Novel Allosteric Activators for Ferroptosis Regulator Glutathione Peroxidase 4.

Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin

Ferroptosis‐modulating small molecules for targeting drug‐resistant cancer: Challenges and opportunities in manipulating redox signaling

Protein S-glutathionylation confers cell resistance to ferroptosis

GPX4 in cell death, autophagy, and disease